IGF::OT::IGF - PAUL C. ANDERSON MEDICINAL CHEMISTRY CONSULTANT SUPPORT SERVICES

IGF::OT::IGF - PAUL C. ANDERSON 药物化学顾问支持服务

• 批准号: 10329705
• 负责人: PAUL C ANDERSON
• 金额: $ 4.5万
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-28 至 2022-02-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10329705
• 关键词: Address; Area; Biological; Biological Assay; Biology; Chemical Structure; Chemistry; Chronic; Clinical Research; Clinical Trials; Consult; Contractor; Contracts; Data; Development; Development Plans; Disease; Drug Industry; Drug Modelings; Electronic Mail; Feedback; Funding; Helping to End Addiction Long-term; Hour; Individual; Industry; Institutes; Investigational Drugs; Knee Osteoarthritis; Lead; Methodology; Neurosciences; Neurosciences Research; Opiate Addiction; Pain; Pain management; Perioperative; Pharmaceutical Chemistry; Pharmaceutical Preparations; Preparation; Principal Investigator; Process; Quality of life; Reporting; Research; Research Contracts; Research Personnel; Role; Seasons; Services; Speed; Strategic Planning; Teleconferences; Telephone; Testing; Therapeutic; Time; United States National Institutes of Health; Visit; Work; chronic musculoskeletal pain; clinical pain; design; drug development; drug discovery; improved; indexing; innovation; lead optimization; meetings; member; nervous system disorder; novel; preclinical safety; programs; symposium; virtual

The NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a virtual pharma (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT). This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. It’s part of the program that establishes novel treatment options for a variety of pain conditions to improve quality of life and reduce opioid dependency. The program studies a broad range of pain conditions, including chronic overlapping pain conditions, chronic musculoskeletal pain, perioperative pain, and knee osteoarthritis.

代表16个NIH研究所和中心的NIH神经科学研究蓝图宣布了神经治疗学的巨大挑战，以解决神经系统疾病有效药物的缺乏。为了迎接这一重大挑战，NIH蓝图正在开创一种新的药物开发模式，该网络将行业药物开发专业知识与创新疾病生物学相结合，这是NIH资助研究的优势。蓝图神经治疗网络将作为一个虚拟制药公司运作（http：//neuroscienceblueprint.nih.gov/bpdrugs/index.htm）。具有令人信服的治疗原理和药物开发项目起始材料的神经科学研究人员（主要研究者）将与设计和指导药物开发计划的高级，行业经验丰富的顾问相匹配。主要研究者将进行生物活性测定和生物学工作，由NIH通过单独合同确定和资助的合同研究组织（CRO）将实施所有其他药物开发活动。参与项目的主要研究者、顾问、NIH工作人员和CRO工作人员将组成牵头开发团队（LDT）。 这项研究是NIH帮助结束长期成瘾（HEAL）计划的一部分，旨在加速科学解决方案，以了解疼痛的基础并加强临床疼痛管理。这是该计划的一部分，该计划为各种疼痛状况建立了新的治疗方案，以改善生活质量并减少阿片类药物依赖。 该计划研究了广泛的疼痛状况，包括慢性重叠疼痛状况，慢性肌肉骨骼疼痛，围手术期疼痛和膝关节骨关节炎。